Increasing IBD Patient Participation In Clinical Trials
North American Precis Syndicate
The more people participate in clinical trials, the sooner less expensive, more effective treatments can be created for all sorts of health conditions. (NAPS)
(NAPSI)—According to the National Institutes of Health, over a
quarter million clinical trials are currently being conducted in the U.S.
Clinical trials are research studies that involve people. Through clinical
trials, researchers find ways to improve existing treatments or test new
treatment options for patients to improve quality of life for people with a
specific disease. Clinical trials are one of the final stages of a long and
careful research process, which often begins in a lab where scientists first
develop and test new ideas. Clinical trials lead to new and better treatments
for people with all kinds of conditions.
One problem, however, is recruiting people to participate. The vast
majority of clinical trials experience delays due to enrollment challenges.
This is especially true for those with inflammatory bowel diseases (IBD) such
as Crohn’s disease and ulcerative colitis.
To help, the Crohn’s & Colitis
Foundation (the Foundation) created a dedicated Clinical Trials Community for
IBD, made possible by support from AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech,
Inc., Gilead Sciences, Inc., and Takeda Pharmaceuticals U.S.A., Inc. It’s
designed to educate patients, caregivers, and health care providers about the
clinical trial process, its value, and how to address barriers that exist in
The Foundation discovered that some people see trials as a last resort and
a treatment option that could potentially compromise their own health.
“These recruitment difficulties cause delays in attaining the
critical data needed to move the drug development process forward,”
explained Michael Osso, president and CEO of the
Foundation. “Our Clinical Trials Community will provide education and
resources to help overcome these challenges and accelerate treatment options
“We know through our research that patients would be willing to
participate in clinical trials if they were able to learn more about the
purpose and importance of clinical trial research,” Osso
added. “With a dedicated, singular resource, we are empowering patients
to make decisions that are right for them, cultivating a culture of citizen
scientists and creating opportunities for patients to support research that
affects the whole IBD community.”
The Clinical Trials Community aims to:
• Inform patients about the different phases and processes involved
in clinical trial participation
• Lessen the fears associated with clinical trials, leaving patients
better informed to make decisions about trial participation
• Equip patients with the knowledge to engage in more robust
conversations with their providers about clinical trials.
The program includes a website, a clinical trial video series, IBD
clinical trial finder, Patient Stories webpage, and research findings.
Additional resources will be added as the community grows.
For further information, visit www.crohnscolitisfoundation.org/clinicaltrials,
call (888) 694-8872, or e-mail email@example.com.
““With a dedicated, singular resource we are
empowering patients to make decisions that are right for them, cultivating a
culture of citizen scientists and creating opportunities for patients to
support research that affects the whole IBD community.” http://bit.ly/2qBgS4a”
On the Net:North American Precis Syndicate, Inc.(NAPSI)